<DOC>
	<DOCNO>NCT00002855</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining hormone therapy chemotherapy androgen suppression may kill tumor cell . It yet know treatment regimen effective prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy plus hormone therapy versus androgen suppression alone initial therapy patient prostate cancer metastatic remove surgically .</brief_summary>
	<brief_title>Chemotherapy Plus Hormone Therapy Versus Androgen Suppression Treating Patients With Metastatic Unresectable Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical benefit , measure time progression overall survival , chemo/hormonal therapy compare androgen ablation alone , give initial systemic treatment patient acinar adenocarcinoma prostate amenable local therapy . - Validate clinical significance PSA criterion progression . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . - Arm I : Patients treat medical surgical castration follow anti-androgen therapy either flutamide , bicalutamide , nilutamide . - Arm II : Patients receive chemo/hormonal therapy 3 eight week course , follow total androgen blockade . Each course consist 6 week cytotoxic therapy doxorubicin , ketoconazole , vinblastine , estramustine follow 2 week rest . These patient also maintain hydrocortisone treatment rest . Patients arm II long-term central venous access device insert . PROJECTED ACCRUAL : A total 368 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Nilutamide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven acinar adenocarcinoma prostate Metastatic locally advance disease either appropriately treat surgery radiation , recur follow previous `` definitive '' local therapy No CNS metastases No histologic subtypes , pure ductal component small cell carcinoma Elevated PSA ( least 1.0 ng/mL patient prior prostatectomy 4.0 ng/mL prostate place ) PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 02 Life expectancy : At least 3 year Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Conjugated bilirubin great 0.8 mg/dL total bilirubin great 1.5 mg/dL Transaminase great 4 time upper limit normal Renal : Creatinine clearance least 40 mL/min Cardiovascular : No evidence bifascicular block EKG No evidence active ischemia EKG No prior history transient ischemic attack No evidence congestive heart failure Other : No active peptic ulcer disease No regular use antacid H2 blockers No known predict achlorhydria No concurrent use terfenadine , astemizole , omeprazole , cisapride No second malignancy unless curatively treat No history deep venous thrombosis No history pulmonary embolism No serious comorbidity HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic systemic therapy Endocrine therapy : Prior androgen deprivation therapy allow give 6 month downstage primary No androgen deprivation therapy within 1 year prior study Radiotherapy : No prior cytotoxic systemic therapy ( include systemic strontium89 irradiation ) Prior definitive radiotherapy prostate and/or one metastatic site allow At least 8 week since radiotherapy pelvis At least 3 week since radiotherapy single metastatic site Surgery : Prior prostatectomy allow Other : No concurrent antianginal therapy aggressive anticoagulant</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>